Abbonarsi

Electrocardiographic Morphology-Voltage-P-Wave-Duration (MVP) Score to Select Patients for Continuous Atrial Fibrillation Screening to Prevent Stroke - 18/09/23

Doi : 10.1016/j.amjcard.2023.08.042 
Lucas Yixi Xing, MD a, b, Søren Zöga Diederichsen, MD, PhD a, c, Søren Højberg, MD, PhD c, Derk Krieger, MD, PhD d, e, Claus Graff, MSc, PhD f, Morten Salling Olesen, MSc, PhD a, g, Jonas Bille Nielsen, MD, PhD a, Axel Brandes, MD, DMSc h, i, j, Lars Køber, MD, DMSc a, k, Ketil Jørgen Haugan, MD, PhD b, Jesper Hastrup Svendsen, MD, DMSc a, k, ⁎
a Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark 
b Department of Cardiology, Zealand University Hospital - Roskilde, Roskilde, Denmark 
c Department of Cardiology, Copenhagen University Hospital - Bispebjerg, Copenhagen, Denmark 
d Department of Neurology, Mediclinic City Hospital, Dubai, United Arabic Emirates 
e Department of Neuroscience, Mohammed Bin Rashid University of Medicine and Health Science, Dubai, United Arabic Emirates 
f Department of Health Science and Technology, Aalborg University, Aalborg, Denmark 
g Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark 
h Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark 
i Department of Cardiology, Odense University Hospital, Odense, Denmark 
j Department of Cardiology, Esbjerg Hospital - University Hospital of Southern Denmark, Esbjerg, Denmark 
k Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark 

⁎Corresponding author: Tel: +45 3545 8061.

Riassunto

Morphology-voltage-P-wave-duration (MVP) score combining P-wave duration (PWD), P-wave voltage in lead I (PWVI), and interatrial block (IAB) has been demonstrated to predict atrial fibrillation (AF). Therefore, this study aimed to examine MVP score and its P-wave components as potential predictors of AF screening effects on stroke prevention. This was a secondary analysis of the LOOP Study (Atrial Fibrillation detected by Continuous ECG Monitoring using Implantable Loop Recorder to prevent Stroke in High-risk Individuals) which randomized older persons (aged 70 to 90 years) with additional stroke risk factors to either continuous monitoring with implantable loop recorder and anticoagulation upon detection of AF episodes ≥6 minutes (the intervention group), or usual care. A total of 5,759 participants were included in the present analysis, where PWD, PWVI, and IAB were determined through a computerized analysis of 12-lead electrocardiogram and further employed to calculate baseline MVP score (0 to 6) for each participant. In total, 305 (5.3%) had stroke or systemic embolism during follow-up, with a higher risk in the group with MVP score 5 to 6 than those having score 0 to 2 (hazard ratio (HR) 1.54 [95% confidence interval (CI) 1.01 to 2.35]). This risk increase was mainly upheld by participants with IAB (HR 1.62 [95% CI 1.11 to 2.36] for IAB vs no IAB) and with longer PWD (HR 1.37 [95% CI 1.07 to 1.75] for >110 vs ≤110 ms). Compared with usual care, implantable loop recorder screening did not significantly reduce the risk of stroke or systemic embolism in any MVP risk categories (HR 0.80 [95% CI 0.60 to 1.08] for MVP score 0 to 2, 0.54 [95% CI 0.16 to 1.85] for MVP score 3 to 4, and 0.89 [95% CI 0.35 to 2.25] for MVP score 5 to 6; pinteraction = 0.78). In conclusion, a higher MVP score was associated with an increased stroke risk, but it did not demonstrate an association with effects of AF screening on stroke prevention. These findings should be considered hypothesis-generating and warrant further study.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : atrial fibrillation, electrocardiogram, screening, stroke, P-wave


Mappa


 Funding: The LOOP Study was supported by Innovation Fund Denmark [grant No. 12-1352259], the Research Foundation for the Capital Region of Denmark, The Danish Heart Foundation [grant No. 11-04-R83-A3363-22625], Aalborg University Talent Management Program, Arvid Nilssons Fond, Skibsreder Per Henriksen, R og Hustrus Fond, the European Union's Horizon 2020 program [grant No. 847770 to the AFFECT-EU consortium], Læge Sophus Carl Emil Friis og hustru Olga Doris Friis’ Legat, and an unrestricted grant from Medtronic. The employment of the first author, LYX, is funded by the AFFECT-EU consortium and thereby the European Union's Horizon 2020 program [grant No. 847770].


© 2023  The Author(s). Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 205

P. 457-464 - ottobre 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Prevalence of Heart Failure With Preserved Ejection Fraction in Patients Undergoing Atrial Fibrillation Ablation Based on Resting and Post-Tachycardia Pacing Left Atrial Pressure
  • Paul Chacko, Sapan Bhuta, Chandramohan Meenakshisundaram, Abdelmoniem Moustafa, Alexander Davis, Rajesh Gupta
| Articolo seguente Articolo seguente
  • Frailty Is Common in Heart Transplant Candidates But Is Not Associated With Clinical Events and Is Reversible After Heart Transplantation
  • Ana Ayesta, María Jesús Valero-Masa, María Teresa Vidán, Javier Segovia-Cubero, María Dolores García-Cosío, Jorge V. López-Ibor, Pedro Caravaca, Raquel Luna-López, Laura Pérez-Gómez, Jorge Nuche, Javier Martínez-Díaz, Juan Delgado, Manuel Gómez-Bueno, Clara Fernández-Cordón, Juan Carlos López-Azor, Manuel Martínez-Sellés

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.